阿帕替尼单药治疗晚期恶性肿瘤的疗效及不良反应分析

目的:分析阿帕替尼（apatinib,YN968D1）单药治疗晚期恶性肿瘤的疗效及不良反应。方法:检索Embase、PubMed、中国知网数据库，使用RStudio-3.5.1对纳入资料进行累积率的统计分析。结果:共检出文献1 260篇。根据纳入及排除标准，最终纳入194篇，包括118篇中文文献和76篇英文文献，总病例数为6 740例。结果显示，阿帕替尼单药治疗晚期胃癌、肺癌、乳腺癌、大肠癌、肉瘤的6个月PFS累积生存率分别为15%、26%、31%、24%、50%；单药治疗晚期肺癌、乳腺癌、大肠癌、肉瘤的12个月OS累积生存率分别为27%、38%、30%、45%。阿帕替尼常见不良反应有高血压、手足综合征和蛋白尿，累积发生率分别为39%、32%、28%。结论:阿帕替尼用于晚期恶性肿瘤的二线及以上治疗，具有客观有效性及安全性。

Efficacy and safety of apatinib monotherapy in patients with advanced malignancies

Objective:To evaluate the efficacy and safety of apatinib(apatinib,YN968D1)monotherapy in advanced malignant tumors with second-line or above treatments failure.Methods:Embase,PubMed and CNKI databases were searched.RStudio-3.5.1 was used to conduct statistical analysis on the pooled rate of the included data.Results:1 260 literatureswere searched and 194 literatures were finally included,involving 118 literatures in Chinese and 76 literatures in English.The number of total cases in this study was 6 740.The results showed that the pooled survival ratio of 6-month PFS was 15% in gastric cancer,26% in lung cancer,31% in breast carcinoma,24% in colorectal cancer and 50% in sarcoma respectively.The pooled survival ratio of 12-month OS was 27% in lung cancer,45% in sarcoma,38% in breast carcinoma,30% in colorectal cancer respectively.The common AEs were hypertension,hand-foot syndrome and proteinuria,with a pooled incidence ratio of 39%,32% and 28% respectively.Conclusion:Apatinib was effective and safe in treating advanced malignancies that had failed second-line or above treatments.